WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Exchange
Industry
Zen Score
Market Cap
Price
1d %
EBITDA
P/E
D/E
ELEV
ELEVATION ONCOLOGY INC
NASDAQ
Biotechnology
$184.87M$3.80-5.24%-$45.64M-2.84x0.63
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
NASDAQ
Biotechnology
$2.70B$42.19-0.14%-$43.97M-57.79x0.03
ONCT
ONCTERNAL THERAPEUTICS INC
NASDAQ
Biotechnology
$26.22M$8.863.02%-$39.31M-0.66x0.22
ADCT
ADC THERAPEUTICS SA
NYSE
Biotechnology
$389.54M$4.72-0.84%-$151.36M-1.61x-3.39
TSBX
TURNSTONE BIOLOGICS CORP
NASDAQ
Biotechnology
$60.52M$2.62-3.32%-$52.69M-0.55x0.14
IRON
DISC MEDICINE INC
NASDAQ
Biotechnology
$708.10M$28.69-4.43%-$75.94M-8.39x0.07
TRML
TOURMALINE BIO INC
NASDAQ
Biotechnology
$396.24M$15.45-1.34%-$41.97M-1.74x0.03
TRDA
ENTRADA THERAPEUTICS INC
NASDAQ
Biotechnology
$408.25M$12.152.02%$14.90M-60.75x0.94
ENTA
ENANTA PHARMACEUTICALS INC
NASDAQ
Biotechnology
$281.80M$13.320.68%-$124.91M-2.03x1.23
ADIL
ADIAL PHARMACEUTICALS INC
NASDAQ
Biotechnology
$7.83M$1.93-11.06%-$5.12M-0.54x0.16
SONN
SONNET BIOTHERAPEUTICS HOLDINGS INC
NASDAQ
Biotechnology
$5.59M$1.822.82%-$14.38M-0.18x1.08
ACLX
ARCELLX INC
NASDAQ
Biotechnology
$2.73B$51.65-5.23%-$44.26M-35.14x0.70
TENX
TENAX THERAPEUTICS INC
NASDAQ
Biotechnology
$7.11M$3.63-1.36%-$7.68M-0.12x0.44
OBIO
ORCHESTRA BIOMED HOLDINGS INC
NASDAQ
Biotechnology
$166.01M$4.64-1.49%-$48.20M-3.14x0.40
NKTR
NEKTAR THERAPEUTICS
NASDAQ
Biotechnology
$227.69M$1.24-6.06%-$243.11M-0.86x2.04
ACRV
ACRIVON THERAPEUTICS INC
NASDAQ
Biotechnology
$212.56M$9.39-10.91%-$59.07M-3.43x0.14
ABUS
ARBUTUS BIOPHARMA CORP
NASDAQ
Biotechnology
$488.22M$2.72-0.37%-$70.99M-6.18x0.36
PYXS
PYXIS ONCOLOGY INC
NASDAQ
Biotechnology
$241.83M$4.16-8.17%-$71.20M-2.25x0.38
ANTX
AN2 THERAPEUTICS INC
NASDAQ
Biotechnology
$73.53M$2.473.78%-$64.68M-0.90x0.11
LIPO
LIPELLA PHARMACEUTICALS INC
NASDAQ
Biotechnology
$4.49M$0.720.70%-$4.61M-0.93x0.14
CTXR
CITIUS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$119.96M$0.75-6.34%-$37.41M-2.90x0.14
AEZS
AETERNA ZENTARIS INC
NASDAQ
Biotechnology
$9.47M$1.95-0.36%-$16.38M-0.57x1.03
AVTE
AEROVATE THERAPEUTICS INC
NASDAQ
Biotechnology
$614.38M$22.052.08%-$75.37M-7.68x0.16
CYTO
ALTAMIRA THERAPEUTICS LTD
NASDAQ
Biotechnology
$2.09M$1.41-5.73%-$2.31M-0.16x0.19
GRTS
GRITSTONE BIO INC
NASDAQ
Biotechnology
$72.27M$0.74-0.94%-$112.80M-0.61x2.43
IKT
INHIBIKASE THERAPEUTICS INC
NASDAQ
Biotechnology
$13.21M$2.04-2.86%-$18.85M-0.57x0.32
JSPR
JASPER THERAPEUTICS INC
NASDAQ
Biotechnology
$325.23M$21.59-6.98%-$62.94M-3.49x0.21
VALN
VALNEVA SE
NASDAQ
Biotechnology
$526.69M$7.58-6.73%-$81.85M-4.78x2.59
UBX
UNITY BIOTECHNOLOGY INC
NASDAQ
Biotechnology
$25.18M$1.50-0.66%-$36.23M-0.56x1.31
IGC
IGC PHARMA INC
NYSEMKT
Biotechnology
$31.23M$0.492.94%-$13.52M-1.88x0.24
NUVL
NUVALENT INC
NASDAQ
Biotechnology
$4.02B$62.76-0.48%-$126.22M-28.92x0.05
TCON
TRACON PHARMACEUTICALS INC
NASDAQ
Biotechnology
$4.46M$1.96-7.11%$3.75M-0.89x-13.49
IONS
IONIS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$5.93B$40.68-0.32%-$230.01M-15.89x6.73
VBIV
VBI VACCINES INC
NASDAQ
Biotechnology
$18.03M$0.630.63%-$84.45M-0.11x10.55
GLUE
MONTE ROSA THERAPEUTICS INC
NASDAQ
Biotechnology
$293.40M$5.85-1.18%-$128.79M-2.22x0.70
DAWN
DAY ONE BIOPHARMACEUTICALS INC
NASDAQ
Biotechnology
$1.31B$14.96-5.02%-$188.53M-6.31x0.09
SEEL
SEELOS THERAPEUTICS INC
NASDAQ
Biotechnology
$4.58M$0.34-0.89%-$37.75M-0.04x-1.16
SGMO
SANGAMO THERAPEUTICS INC
NASDAQ
Biotechnology
$91.42M$0.515.36%-$240.71M-0.35x1.00
ASND
ASCENDIS PHARMA A
NASDAQ
Biotechnology
$8.09B$140.17-0.51%-$442.12M-15.25x-6.67
FENC
FENNEC PHARMACEUTICALS INC
NASDAQ
Biotechnology
$253.11M$9.34-2.40%-$12.65M-15.57x-3.31
PYPD
POLYPID LTD
NASDAQ
Biotechnology
$7.28M$4.402.33%-$21.05M0.26x-8.33
TNXP
TONIX PHARMACEUTICALS HOLDING CORP
NASDAQ
Biotechnology
$13.52M$0.161.91%-$112.37M-0.02x0.46
LGVN
LONGEVERON INC
NASDAQ
Biotechnology
$4.83M$1.92-4.48%-$20.47M-0.19x0.79
MOR
MORPHOSYS AG
NASDAQ
Biotechnology
$2.71B$17.98-0.39%-$41.75M-11.96x40.31
BTAI
BIOXCEL THERAPEUTICS INC
NASDAQ
Biotechnology
$84.09M$2.757.84%-$165.42M-0.45x-2.30
EYEN
EYENOVIA INC
NASDAQ
Biotechnology
$27.06M$0.577.53%-$24.11M-0.87x2.20
MRSN
MERSANA THERAPEUTICS INC
NASDAQ
Biotechnology
$394.23M$3.25-2.69%-$163.30M-2.20x5.13
FNCH
FINCH THERAPEUTICS GROUP INC
NASDAQ
Biotechnology
$3.60M$2.24-5.08%-$75.60M-0.05x1.42
CMMB
CHEMOMAB THERAPEUTICS LTD
NASDAQ
Biotechnology
$9.66M$0.68-2.86%-$24.15M-0.33x0.30
SLN
SILENCE THERAPEUTICS PLC
NASDAQ
Biotechnology
$896.00M$22.642.82%-$60.37MN/A4.50
MBRX
MOLECULIN BIOTECH INC
NASDAQ
Biotechnology
$10.36M$4.652.79%-$29.64M-0.31x0.47
TLSA
TIZIANA LIFE SCIENCES LTD
NASDAQ
Biotechnology
$68.11M$0.674.06%-$15.34M-4.44x0.35
VIRI
VIRIOS THERAPEUTICS INC
NASDAQ
Biotechnology
$8.38M$0.44-3.33%-$5.30M-1.55x0.09
VTYX
VENTYX BIOSCIENCES INC
NASDAQ
Biotechnology
$264.86M$4.472.76%-$192.02M-1.35x0.14
INSM
INSMED INC
NASDAQ
Biotechnology
$3.61B$24.32-1.94%-$645.53M-4.55x-5.01
THAR
THARIMMUNE INC
NASDAQ
Biotechnology
$4.43M$0.38-0.26%-$9.30M-0.05x0.20
MGTX
MEIRAGTX HOLDINGS PLC
NASDAQ
Biotechnology
$326.87M$5.091.60%-$57.05M-3.42x1.37
SCPX
SCORPIUS HOLDINGS INC
NYSEMKT
Biotechnology
$4.09M$0.16-1.26%-$48.05M-0.08x1.01
RPHM
RENEO PHARMACEUTICALS INC
NASDAQ
Biotechnology
$58.15M$1.74-1.14%-$76.86M-0.69x0.21
MLYS
MINERALYS THERAPEUTICS INC
NASDAQ
Biotechnology
$560.34M$11.295.02%-$71.90M-5.67x0.04
HLVX
HILLEVAX INC
NASDAQ
Biotechnology
$611.32M$12.303.71%-$119.02M-4.05x0.30
XTLB
XTL BIOPHARMACEUTICALS LTD
NASDAQ
Biotechnology
$13.30M$2.440.00%-$1.35M-12.20x0.05
SLDB
SOLID BIOSCIENCES INC
NASDAQ
Biotechnology
$328.48M$8.70-6.05%-$93.43M-1.80x0.30
PEPG
PEPGEN INC
NASDAQ
Biotechnology
$340.85M$10.54-11.06%-$77.37M-3.19x0.32
GHRS
GH RESEARCH PLC
NASDAQ
Biotechnology
$573.87M$11.03-1.43%-$34.55M-16.22x0.03
ONCY
ONCOLYTICS BIOTECH INC
NASDAQ
Biotechnology
$78.89M$1.062.91%-$20.04M-3.52x0.41
TNYA
TENAYA THERAPEUTICS INC
NASDAQ
Biotechnology
$339.19M$4.320.70%-$112.27M-2.57x0.22
IMMX
IMMIX BIOPHARMA INC
NASDAQ
Biotechnology
$57.81M$2.19-0.90%-$15.39M-2.46x0.23
VIRX
VIRACTA THERAPEUTICS INC
NASDAQ
Biotechnology
$33.66M$0.86-5.72%-$46.86M-0.65x2.10
XFOR
X4 PHARMACEUTICALS INC
NASDAQ
Biotechnology
$211.60M$1.265.00%-$93.32M-2.21x1.88
ENLV
ENLIVEX THERAPEUTICS LTD
NASDAQ
Biotechnology
$24.55M$1.32-5.71%-$28.56M-0.85x0.22
KPTI
KARYOPHARM THERAPEUTICS INC
NASDAQ
Biotechnology
$134.63M$1.17-8.59%-$118.42M-0.94x-2.77
GLSI
GREENWICH LIFESCIENCES INC
NASDAQ
Biotechnology
$155.44M$12.07-6.36%-$8.89M-17.49x0.04
WINT
WINDTREE THERAPEUTICS INC
NASDAQ
Biotechnology
$3.14M$0.340.59%-$19.75M-0.07x8.56
PHVS
PHARVARIS NV
NASDAQ
Biotechnology
$1.00B$19.164.02%-$103.93M-6.78x0.04
CMND
CLEARMIND MEDICINE INC
NASDAQ
Biotechnology
$3.76M$1.190.59%-$7.85M-0.04x1.00
CRIS
CURIS INC
NASDAQ
Biotechnology
$84.34M$14.31-5.98%-$45.81M-1.60x2.93
EDSA
EDESA BIOTECH INC
NASDAQ
Biotechnology
$14.11M$4.452.06%-$7.52M-1.69x0.34
BLTE
BELITE BIO INC
NASDAQ
Biotechnology
$974.47M$33.43-3.38%-$31.20M-28.09x0.05
CALC
CALCIMEDICA INC
NASDAQ
Biotechnology
$43.18M$4.020.25%-$34.30M-0.52x0.49
CGEN
COMPUGEN LTD
NASDAQ
Biotechnology
$167.99M$1.901.06%N/A-9.05x0.85
APLT
APPLIED THERAPEUTICS INC
NASDAQ
Biotechnology
$463.78M$4.38-7.59%-$119.41M-3.08x-4.20
GNTA
GENENTA SCIENCE SPA
NASDAQ
Biotechnology
$71.06M$3.90-0.38%-$12.28M-5.60x0.09
NERV
MINERVA NEUROSCIENCES INC
NASDAQ
Biotechnology
$17.34M$2.48-0.80%-$29.97M-0.54x-3.00
CDMO
AVID BIOSERVICES INC
NASDAQ
Biotechnology
$404.10M$6.39-1.99%$604.00k-37.59x1.48
CAPR
CAPRICOR THERAPEUTICS INC
NASDAQ
Biotechnology
$157.31M$5.01-0.79%-$21.22M-6.04x1.60
OPT
OPTHEA LTD
NASDAQ
Biotechnology
$192.70M$3.30-2.94%-$134.99M-1.28x-17.85
AZTR
AZITRA INC
NYSEMKT
Biotechnology
$5.62M$0.202.63%-$10.67M-0.11x0.76
PDSB
PDS BIOTECHNOLOGY CORP
NASDAQ
Biotechnology
$97.02M$2.65-8.79%-$42.87M-1.90x1.27
RARE
ULTRAGENYX PHARMACEUTICAL INC
NASDAQ
Biotechnology
$3.49B$42.37-2.33%-$582.46M-5.14x4.41
SYRE
SPYRE THERAPEUTICS INC
NASDAQ
Biotechnology
$1.17B$32.41-8.91%-$337.85M-0.66x0.40
RLYB
RALLYBIO CORP
NASDAQ
Biotechnology
$66.55M$1.765.39%-$74.41M-0.96x0.09
BMEA
BIOMEA FUSION INC
NASDAQ
Biotechnology
$389.40M$10.85-2.78%-$113.05M-3.15x0.18
ALLK
ALLAKOS INC
NASDAQ
Biotechnology
$94.03M$1.070.94%-$188.42M-0.50x0.44
SLRX
SALARIUS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$2.13M$0.491.65%-$12.53M-0.13x0.25
CYCC
CYCLACEL PHARMACEUTICALS INC
NASDAQ
Biotechnology
$2.35M$1.78-3.78%-$25.52M-0.07x13.51
APGE
APOGEE THERAPEUTICS INC
NASDAQ
Biotechnology
$2.38B$46.91-2.98%-$83.90M-13.96x0.06
ENVB
ENVERIC BIOSCIENCES INC
NASDAQ
Biotechnology
$6.43M$0.88-6.08%-$16.86M-0.11x1.20
FWBI
FIRST WAVE BIOPHARMA INC
NASDAQ
Biotechnology
$5.27M$2.60-8.45%-$15.74M-0.05x0.91
GNPX
GENPREX INC
NASDAQ
Biotechnology
$4.07M$2.13-4.01%-$30.85M-0.09x0.44

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -29.07% over the past year, underperforming other biotech stocks by -4 percentage points.

Incyte has an average 1 year price target of $73.92, an upside of 41.2% from Incyte's current stock price of $52.35.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Incyte, 25% have issued a Strong Buy rating, 16.67% have issued a Buy, 58.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -10.83% over the past year, overperforming other biotech stocks by 14 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $37.33, an upside of 26.98% from Harmony Biosciences Holdings's current stock price of $29.40.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 16.67% have issued a Sell rating, and 16.67% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock lose -5.18% over the past year, overperforming other biotech stocks by 20 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 173.33% from Voyager Therapeutics's current stock price of $7.50.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 14.22%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 53.85%, which is 40 percentage points higher than the biotech industry average of 14.22%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.12%, which is -13 percentage points lower than the biotech industry average of 14.22%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -0.86% in the last day, and down -6.25% over the last week. Biophytis Sa was the among the top losers in the biotechnology industry, dropping -11.04% yesterday.

Biophytis shares are trading lower after the company announced that it will change the ratio of its American Depositary Shares From 100 to 4,000.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -22.3% in the past year. It has overperformed other stocks in the biotech industry by 3 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has dropped -5.18% in the past year. It has overperformed other stocks in the biotech industry by 20 percentage points.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 71 points higher than the biotech industry average of 15. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -29.07% in the past year. It has underperformed other stocks in the biotech industry by -4 percentage points.

Are biotech stocks a good buy now?

48.65% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 90.05% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 15.81x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.